Consulta: subjectFacets:"Reserpine"
Registros recuperados: 2
Data/hora: 05/06/2024 17:19:25

Effect of daidzein on Parkinson disease induced by reserpine in rats
Provedor de dados: 60
Autores: Goel,Radha; Chaudhary,Rabia.
Parkinson disease is a neurodegenerative disorder characterised by the cardinal symptoms of stiffness, resting tremor, slowness (bradykinesia) and reduction of movement (hypokinesia). Involvement of oxidative damage has been reported in the pathophysiology of Parkinson disease and its related complications. The purpose of this study was to examine the effect of daidzein to quench the free radicals produced as a result of the increased oxidative stress in Parkinson disease.Parkinson disease is induced by administration of reserpine (5 mg/kg/day, i.p) for 5 consecutive days. The symptoms of PD such as tremors, akinesia and rigidity were evaluated. The effect was evaluated by assessing various behavioral parameters (grip strength and locomotor activity),...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Daidzein; Reserpine; Carbidopa and Levodopa combination; Parkinson.
Ano: 2020
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100559

8-Propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one: A new coumarin with monoamine oxidase B inhibitory activity and possible anti-parkinsonian effects
Provedor de dados: 60
Autores: Olaya,María del Pilar; Vergel,Nadezdha Esperanza; López,Jose Luis; Viña,Dolores; Guerrero,Mario Francisco.
Parkinson’s disease is a common neurodegenerative disorder. In this study, the monoamine oxidase inhibitory activity and potential anti-parkinsonian effects of 8-propyl-6H-[1,3]dioxolo[4,5-g]chromen-6-one (FCS303), a new synthetic coumarin, were evaluated. To do this, we used the reserpine model of Parkinson’s disease, an assay of levodopa/carbidopa potentiation, the catalepsy model of haloperidol, and an in vitro assay against monoamine oxidase (MAO) activity. Additionally, lipid peroxidation and protein carbonyl group quantification was performed in mice brain homogenates previously treated with haloperidol. FCS303 inhibited monoamine oxidase B (MAO-B) with an IC50 of 5.46 ± 0.36 µM; however, there was no effect on monoamine oxidase A (MAO-A). The oral...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Parkinson’s disease; Monoamine oxidase B; Coumarin; Mice; Reserpine; Levodopa; Carbidopa.
Ano: 2020
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100508